iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Stock Short Interest Report for October

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 67,932 shares, a decline of 68.9% from the September 30th total of 218,618 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 164,313 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new position in iShares Genomics Immunology and Healthcare ETF stock. NewEdge Advisors LLC bought a new position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 961 shares of the company’s stock, valued at approximately $32,000.

iShares Genomics Immunology and Healthcare ETF Trading Down 0.5%

NYSEARCA IDNA traded down $0.23 during trading hours on Friday, hitting $42.76. 291,176 shares of the company’s stock traded hands, compared to its average volume of 74,315. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $24.29 and a 52 week high of $43.79. The firm has a market capitalization of $335.67 million, a P/E ratio of 14.76 and a beta of 0.94. The business’s fifty day moving average price is $40.75 and its two-hundred day moving average price is $33.15.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.